Preclinical research findings from UNC Lineberger Comprehensive Cancer Center identified a combination of three different drugs that can be used to boost immunotherapy to fight cancer. This finding may have a significant impact on improving the production of chimeric antigen receptor-T cells for clinical use.
The research findings appeared Jan. 8 in Nature Immunology. The paper’s two corresponding authors are Lineberger researchers Dr. Gianpietro Dotti and postdoctoral research fellow Yang Xu. Feifei Song, another Lineberger postdoctoral research fellow, is the first author.
CAR-T cell immunotherapy involves harvesting immune-system T cells from a patient and genetically re-engineering them in the lab to recognize targets on the surface of cancer cells when they are reinfused into patients. Patients treated with…